Ticker: DRIO

DarioHealth Corp. (NASDAQ: DRIO) - Q2 2025 executive snapshot What's happening: management is cutting operating costs and integrating acquisitions while leaning on a new Callodine credit facility ($32.5M drawn at close) to fund growth. Gross margins improved, but the company remains unprofitable,...

DarioHealth Corp. (NASDAQ: DRIO) has released its quarterly report for the period ending March 31, 2025, illustrating both progress and challenges in its financial landscape. Highlights from the Income Statement: Total Revenues: $6,752,000, an increase of 17.3% from $5,758,000 in Q1 2024. Gross ...